Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells

Cancer Research

Volumn 70, Issue 16, 2010, Pages 6412-6419

  Aleksic, Tamara ^a   Chitnis, Meenali M ^a   Perestenko, Olga V ^a   Gao, Shan ^a   Thomas, Peter H ^a   Turner, Gareth D ^b   Protheroe, Andrew S ^c   Howarth, Mark ^d   Macaulay, Valentine M ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c Churchill Hospital   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZ 12253801; CLATHRIN; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ALPHA SUBUNIT; SOMATOMEDIN C RECEPTOR BETA SUBUNIT; UNCLASSIFIED DRUG;

ARTICLE; BREAST LESION; CANCER CELL; CELL NUCLEUS; CELL PROLIFERATION; CELL TRANSPORT; CHROMATIN; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; ENDOCYTOSIS; HUMAN; HUMAN CELL; IC 50; KIDNEY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; TRANSCRIPTION REGULATION; 3T3 CELL LINE; ANIMAL; BREAST TUMOR; CELL MEMBRANE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MOUSE; NEOPLASM; PROSTATE TUMOR; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MICE; NEOPLASMS; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, IGF TYPE 1;

EID: 77955736995     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0052     Document Type: Article

References (24)

1. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008;14:6364-70.
2. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57:1050-93.
3. Vecchione A, Marchese A, Henry P, Rotin D, Morrione A. The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Mol Cell Biol 2003;23:3363-72.
4. Romanelli RJ, LeBeau AP, Fulmer CG, Lazzarino DA, Hochberg A, Wood TL. Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt. J Biol Chem 2007;282:22513-24.
5. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3:802-8.
6. Liao HJ, Carpenter G. Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol Biol Cell 2007;18:1064-72.
7. Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 2006;127:185-97.
8. Massie C, Mills IG. The developing role of receptors and adaptors. Nat Rev Cancer 2006;6:403-9.
9. Chen CW, Roy D. Up-regulation of nuclear IGF-I receptor by short term exposure of stilbene estrogen, diethylstilbestrol. Mol Cell Endocrinol 1996;118:1-8.
10. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:2942-50.
11. Yuen JS, Cockman ME, Sullivan M, et al. The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 2007;26:6499-508.
12. Yuen JS, Akkaya E, Wang Y, et al. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 2009;8:1448-59.
13. Turney BW, Turner GDH, Brewster SF, Macaulay VM. Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. BJU Int. In press 2010.
14. Aleksic T, Feller SM. ã-Secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells. Cell Commun Signal 2008;6:8.
15. Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, Efstratiadis A. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A 2009;106:2359-64.
16. McElroy B, Powell JC, McCarthy JV. The insulin-like growth factor 1 (IGF-1) receptor is a substrate for ã-secretase-mediated intramembrane proteolysis. Biochem Biophys Res Commun 2007;358:1136-41.
17. Sehat B, Andersson S, Girnita L, Larsson O. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 2008;68:5669-77.
18. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1. J Cell Biochem 2006;98:1570-83.
19. Wu A, Chen J, Baserga R. Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes. Oncogene 2008;27:397-403.
20. Sehat B, Tofigh A, Lin Y, et al.SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 2010;3:ra10.
21. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003;63:627-35.
22. Mohr D, Frey S, Fischer T, Guttler T, Gorlich D. Characterisation of the passive permeability barrier of nuclear pore complexes. EMBO J 2009;28:2541-53.
23. Sexton T, Schober H, Fraser P, Gasser SM. Gene regulation through nuclear organization. Nat Struct Mol Biol 2007;14:1049-55.
24. Parker A, Cheville JC, Lohse C, Cerhan JR, Blute ML. Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol 2003;170:420-4.